Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Elevidys has been developed by Sarepta in partnership with pharma giant Roche RHHBY. SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Roche has ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Sarepta already markets three exon-skipping drugs for DMD that have to be taken chronically, but SRP-9001 offers the possibility of a one-shot therapy for the disease. Roche has exclusive rights ...

Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.